Background. Although surgical management of the axilla for breast cancer continues to evolve, axillary lymphadenectomy remains the standard of care for women with advanced nodal disease. We sought to evaluate national patterns of care in axillary surgery, and its association with overall survival (OS) among women with N2-3 invasive breast cancer. Methods. Women (18-90 years) with clinical N2-3 invasive breast cancer who underwent axillary surgery were identified from the National Cancer Data Base (NCDB) from 2004 to 2013. Axillary surgery was categorized as sentinel lymph node biopsy (SLNB, 1-5 nodes) or axillary lymph node dissection (ALND, C 10 nodes). Patient and treatment characteristics, trends over time, and overall survival (OS) were compared by surgical treatment. Results. Overall, 22,156 patients were identified. At diagnosis, 68.5% had cN2 and 31.5% had cN3 disease. Treatment included: lumpectomy (27%), mastectomy (73%), adjuvant chemotherapy (53.4%), neoadjuvant chemotherapy (NAC) (39.7%), radiation (74%), and endocrine therapy (54.4%). In total, 9.9% (n = 2190) underwent SLNB and 90.1% (n = 19,966) underwent ALND. Receipt of SLNB was associated with private insurance, grade 3 disease, invasive ductal cancer, NAC, and lumpectomy (all p \ 0.001). After adjustment for known covariates, including chemotherapy use, ALND was associated with improved survival [hazard ratio (HR) 0.68, p \ 0.001] and this effect was similar for N2 and N3 patients (axillary surgery 9 cN-stage interaction p = 0.29). Conclusions. Axillary lymphadenectomy was associated with improved survival in patients presenting with clinical N2-3 invasive breast cancer. Further studies, particularly in the neoadjuvant setting, are needed to identify breast cancer patients with advanced nodal disease who may safely avoid a lesser extent of axillary surgery.
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In treatment of invasive breast cancer, axillary lymph node status has remained the strongest prognostic factor and guide in adjuvant decision-making. [1] [2] [3] Historically, axillary lymph node dissection (ALND) was used as part of routine breast cancer staging. In 1994, Guiliano et al. validated the use of sentinel lymph node biopsy (SLNB) to reliably stage the axilla in clinically node-negative patients, 4, 5 and ALND became limited to women with known axillary nodal metastases for the purpose of local control. [6] [7] [8] [9] [10] [11] Contemporary multimodal treatment of breast cancer has led to further reductions in axillary surgery, even among women with known axillary lymph node metastases. In 2010, results from the ACOSOG Z0011 trial supported the use of SLNB alone among women with clinically node-negative, T1-2 invasive breast cancer undergoing breast conservation with one or two positive sentinel lymph nodes. Among eligible women, completion ALND did not improve overall or disease-free survival or locoregional recurrence rates. 12, 13 In 2014, the EORTC 10981-22023 AMAROS trial demonstrated that axillaryspecific radiotherapy was equivalent to ALND among women with clinically node-negative, T1-2 invasive breast cancer and positive sentinel nodes treated with either breast conservation or mastectomy.
14 Currently enrolling, the Alliance 11202 trial aims to compare ALND versus axillary radiotherapy among women with residual positive sentinel lymph nodes following neoadjuvant chemotherapy, with estimated primary completion date of January 2024. 15 The most recent guidelines from the National Comprehensive Cancer Network (NCCN) state that SLNB alone without further axillary surgery is adequate in the setting of a clinically negative axilla and positive sentinel node biopsy if all of the following criteria are met: T1-2 tumor with one or two positive SLNs, plan for breast conservation therapy and whole-breast radiation therapy (RT), and no receipt of preoperative chemotherapy. 16 Outside of the research setting, ALND continues to be considered the standard of care for women who do not meet these criteria, or those with clinically positive, biopsy-proven axillary metastases. In light of the rapid evolution of surgical management of the axilla, and as the breast cancer community weighs the risk of distant progression against the benefits and harms of local control, uncertainties remain about the role of ALND among women with a greater burden of nodal disease. To this end, we sought to evaluate national patterns of care in axillary surgery, and its association with overall survival (OS), among women with N2-3 invasive breast cancer.
PATIENTS AND METHODS
Adult female patients (age 18-90 years) diagnosed with T1-3, N2-3 invasive breast cancer from 2004 to 2013 were identified from the National Cancer Data Base (NCDB). The NCDB does not capture the specific surgical method of axillary staging for women with breast cancer. Therefore, we categorized axillary staging based on the number of lymph nodes removed as SLNB (1-5 lymph nodes examined) or ALND (10? lymph nodes examined). Patients with noninvasive cancer, metastatic disease at diagnosis (clinical M1), missing or incomplete lymph node dissection data, or 6-9 lymph nodes examined were excluded. Patients who did not undergo surgery of the breast, or had surgery coded as local tumor destruction, surgery not otherwise specified, or unknown were also excluded. The final cohort sample size was N = 22,156.
Patient characteristics are summarized as N (%) and median (interquartile range, IQR) for categorical and continuous variables, respectively, for all patients and by axillary surgery group (ALND or SLNB). Variables were compared between groups using the Chi square test or Student's t test.
Overall survival was defined as time from diagnosis to death. For patients who remained alive throughout the study interval, survival time was censored at date of last follow-up. Kaplan-Meier curves and log-rank tests were used to examine unadjusted differences in survival between groups. Cox proportional hazards models were used to estimate the HR associated with type of axillary surgery after adjustment for known covariates, including age at diagnosis, race, Charlson-Deyo comorbidity score, income level, insurance type, education level, facility location and type, hormone receptor status, clinical T and N stage, grade, histology, use of endocrine therapy, radiotherapy (RT) and chemotherapy, surgery type, and number of positive lymph nodes. A subgroup analysis including only patients who received chemotherapy was conducted to estimate the effect of axillary surgery and chemotherapy sequence on survival. Additional models that included interaction terms of the axillary surgery group with select covariates were conducted to determine if the effect of axillary surgery on overall survival differed between subgroups. Because human epidermal growth factor receptor 2 (HER2) status is frequently missing in this database, a sensitivity analysis was done that excluded that variable from all models. To account for the correlation of patients treated at the same hospital, all adjusted models also included a robust sandwich covariance estimator. Only patients with available data for all covariates in a given model were included in each analysis. Sample sizes are included in the titles for each table and figure. No adjustments were made for multiple testing. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS

Patient and Treatment Characteristics
The final study cohort consisted of 22,156 patients with clinical T1-3, N2-3 invasive breast cancer treated with SLNB or ALND. Median age of the sample was 56 years, and median tumor size was 3.2 cm. Of the patients, 68.5% had clinical N2 disease, and 31.5% had clinical N3 disease. Of the patients, 87% had invasive ductal cancer, and 11.3% had invasive lobular cancer. On histologic review, 6% of patients had grade 1, 32.7% had grade 2, and 54.8% had grade 3 tumor. The majority had hormone receptor-positive disease [53.9% estrogen receptor (ER)?, 65.7% progesterone receptor (PR)?]. Of these women, 27% underwent lumpectomy (n = 5983) and 73% underwent mastectomy (n = 16,173). Of patients, 86.4% received chemotherapy, of whom 39.7% received neoadjuvant chemotherapy and 53.4% received adjuvant chemotherapy. Of patients, 74% received radiation: 22.6% (n = 5003) after lumpectomy and 51.4% (n = 11,397) after mastectomy. In total, 54.4% of all patients and 78% of hormone-receptor positive patients (ER? and/or PR?) received endocrine therapy. Patient and treatment characteristics are summarized in Table 1 .
Predictors of Extent of Axillary Surgery
In total, 90.1% (n = 19,966) of the cohort underwent ALND and 9.9% (n = 2190) underwent SLNB alone. The median number of nodes examined was 3 in the SLNB group versus 17 in the ALND group. Receipt of axillary surgery did not differ based on clinical T-stage (p = 0.05). Factors significantly associated with receipt of SLNB alone compared with ALND included: private insurance (59.9 vs. 55.1%, p \ 0.001), grade 3 disease (61 vs. 54.1%, p \ 0.001), invasive ductal cancer (90.5 vs. 86.6%, p \ 0.001), and receipt of lumpectomy (36 vs. 26%, p \ 0.001). Women who underwent ALND were more likely to have invasive lobular cancer and undergo mastectomy when compared with those treated with SLNB alone (11.7 vs. 7.3% and 74 vs. 64%, p \ 0.001). SLNB was associated with greater use of lumpectomy with radiation compared with those who had ALND (29.2 vs. 21.9%, p \ 0.001). However, ALND was associated with higher likelihood of receiving postmastectomy radiation when compared with SLNB alone (52.5 vs. 41.8%, p \ 0.001).
Receipt of SLNB alone was associated with neoadjuvant chemotherapy use. Among those who underwent SLNB alone, 71.1% (n = 1365) received NAC and 23.2% (n = 445) received adjuvant chemotherapy, while in women who underwent ALND, 36.2% (n = 6231) received NAC and 56.8% (n = 9778) received adjuvant chemotherapy. The overall rate of SLNB alone in the NAC group was 18%. Notably, this rate increased from 13.5% in 2004 to 22% in 2013, whereas the rate of SLNB in those treated with adjuvant chemotherapy did not change appreciably over time, from 4.3% in 2004 to 6.2% in 2013 ( 
Overall Survival
After adjustment for known covariates including histology, hormone-receptor status, surgery of the primary breast tumor, receipt of chemotherapy, radiation, and endocrine therapy, ALND was associated with improved survival compared to SLNB alone for the overall cohort [HR 0.68, 95% confidence interval (CI) 0.56-0.83, p \ 0.001] ( Table 2 ). The effect of ALND versus SLNB on survival did not differ between cN2 versus cN3 patients (axillary surgery 9 cN-stage interaction p = 0.29; Table 3 ). Receipt of lumpectomy was associated with improved overall survival compared to mastectomy (HR = 0.79, p = 0.002), as was use of chemotherapy (HR = 0.48, p \ 0.001) and radiation (HR = 0.68, p \ 0.001) ( Table 2 ). On stratified analysis of women who underwent surgery first (excluding NAC patients), ALND was associated with improved overall survival when compared to SLNB alone (HR 0.66, p \ 0.001). Adjusted overall survival model limited to women who received NAC demonstrated a reduced risk of death with ALND when compared to SLNB alone (HR = 0.60, 95%, CI 0.46-0.80, p \ 0.001) ( Table 4) . Pathologic completed response (pCR) following NAC (ypN0 and ypT0) was associated with improved overall survival (HR = 0.37, p \ 0.001), but importantly, within these exceptional responders, the benefit of ALND remained; ALND was associated with improved overall survival when compared to SLNB alone even after path CR (Table 5) .
Sensitivity Analysis
When HER2 was not included as a covariate in the adjusted survival models, results were similar to those that included HER2 (reported previously). After adjustment for other known covariates including histology, ER/PR status, breast surgery type, chemotherapy, radiation, and endocrine therapy, ALND was still associated with improved overall survival compared with SLNB (HR 0.77, 95% CI 0.68-0.86, p \ 0.001). The effect of ALND versus SLNB on survival did not differ between cN2 versus cN3 patients (axillary surgery 9 cN-stage interaction p = 0.14).
DISCUSSION
Among women with invasive breast cancer, surgical management of the axilla has evolved dramatically in the past 20 years. SLNB replaced ALND for surgical staging in the setting of a clinically negative axilla, and more recently has replaced ALND in women with low-volume nodal disease. 8, 9, 12, 17 The ACOSOG Z0011, AMAROS, and Alliance 11202 trials are collectively identifying breast cancer patients with known axillary nodal metastases who can safely avoid complete lymph node dissection without compromising oncologic outcomes. 14, 15, 18 In this study, we sought to evaluate contemporary treatment patterns for women with breast cancer and advanced axillary nodal disease, in order to understand the uptake and extrapolation of rapidly evolving evidence. Furthermore, we evaluated whether the extent of axillary surgery was associated with overall survival in a subset of breast cancer patients at higher risk of both local and distant recurrence. Our study cohort included women with clinical N2-3 invasive breast cancer, in whom axillary surgery would most likely be employed for the purpose of local control and less likely for the purpose of guiding adjuvant chemo-or-radiotherapy treatment decisions. Despite ALND being standard of care, we found that 10% of women with N2-3 invasive breast cancer underwent surgical removal of five or fewer nodes, and that receipt of NAC or lumpectomy was associated with greater likelihood of avoiding completion lymphadenectomy (defined as removal of C 10 lymph nodes). Of women with N2-3 disease, 18% underwent SLNB alone after neoadjuvant chemotherapy, which increased over time from 13.5% in 2004 to 22% in 2013. This suggests that reductions in the extent of axillary surgery were occurring prior to publication of the Alliance 1071 trial in 2013. 18 Kantor et al. 19 reported a similar trend among 12,063 women with cN1 invasive breast cancer, where rates of SLNB alone increased from 18.9% in 2010 to 33.3% in 2013. The ACOSOG 1071 trial evaluated the feasibility of SLNB among women with clinical N1-2 biopsy-proven invasive breast cancer following neoadjuvant systemic therapy. 18 Among cN1 patients, use of dual-tracer mapping resulted in a false-negative rate (FNR) of 10.8%, which was further improved if at least three SLN were examined (FNR 9.1%). Caudle et al. 20 reported a further reduction in FNR to less than 2% on targeted axillary dissection (TAD), defined as removal of the sentinel lymph nodes plus the biopsy-proven and clipped lymph node, among cN0 patients following NAC. The ongoing Alliance A11202 study is a randomized phase III trial comparing the efficacy of ALND versus axillary radiation in patients with clinical T1-3, N1 invasive breast cancer who remain node positive after neoadjuvant chemotherapy. 15 The sister trial NSABP B-51/RTOG 1304 is enrolling patients with biopsy-proven N1 disease who achieve nodal pCR following NAC, randomizing women to axillary radiation or no further axillary treatment. 21, 22 For women with advanced axillary nodal burden and higher risk of metastatic recurrence, local axillary control could arguably have little impact on overall survival, which would instead be driven by the risk of distant metastatic disease. Our findings demonstrate that, in women who presented with clinical N2-3 invasive breast cancer, axillary lymph node dissection was associated with improved survival (HR 0.68, p \ 0.001) in women treated with neoadjuvant chemotherapy who achieved pCR and those who received adjuvant chemotherapy. This suggests that, although SLNB alone may provide adequate control in the setting of low-volume metastatic disease, axillary clearance may be associated with a survival benefit in patients with higher burden of nodal disease, in whom NAC use may be inadequate for downstaging advanced nodal burden. These findings differ from the results of the NSABP B-04 trial, which examined a subset of women with palpable, suspicious axillary nodes who were randomized to undergo radical mastectomy versus total mastectomy and These estimates are also adjusted for all covariates included in Table 2 The Association of Extent of Axillary Surgery and Survival in Women 25 At 25 years of follow-up, there was no difference in diseasefree or overall survival between these groups, yet a small but statistically insignificant difference in locoregional recurrence was seen in women who underwent lymphadenectomy compared with those without axillary surgery (8 vs. 11%, p = 0.40). As improvements in systemic therapy have led to improved survival after breast cancer, locoregional therapy may matter more or reflect more aggressive multimodal therapy in healthier breast cancer patients with improved prognosis.
More contemporary trials evaluating less extensive axillary surgery have primarily done so in clinically nodenegative patients without palpable axillary nodes. The AMAROS trial demonstrated that, in women with T1-2 primary breast cancer with a clinically negative axilla but a positive sentinel lymph node, axillary radiation therapy provided equivalent local control and overall survival when compared with ALND.
14 After 5 years of follow-up, the axillary recurrence rate was 0.43% in the ALND group versus 1.2% in the radiotherapy group. Importantly, lymphedema was significantly lower in the radiotherapy group. These findings support use of axillary radiotherapy in place of ALND for patients with clinically node-negative axilla with similar oncologic outcomes and lower morbidity. Bonneau et al. 23 evaluated the use of ALND versus SLNB in 9521 patients with three or four metastatic axillary nodes using the United States Surveillance, Epidemiology, and End Results (SEER) database. In that study, there was no difference in overall survival between patients undergoing ALND versus SLNB with three or more metastatic lymph nodes. The authors concluded that ALND was a staging procedure and lacked therapeutic benefit in patients with T1-2 invasive breast cancer and at least three metastatic nodes after SLNB.
There are several limitations to our study that should be noted. As with all retrospective studies, the data are subject to bias. In this setting, women who underwent more aggressive axillary clearance with ALND may have constituted a healthier population of women with advanced breast cancer, or who have received more aggressive therapy overall. Importantly, the NCDB does not capture These estimates are also adjusted for all covariates included in Table 4 the specific surgical method of axillary staging for women with breast cancer. Therefore, we were unable to determine if women underwent a sentinel lymph node biopsy (SLNB)) with nodal mapping or an anatomic axillary lymph node dissection (ALND) that included level 1 and 2 lymph nodes or higher. As a result, we relied on the number of lymph nodes removed as a surrogate for the extent of axillary surgery based on previously published studies. 24, 25 Additionally, we were unable to determine local or disease-free recurrences, which differ by tumor phenotype and receipt of targeted therapies. [26] [27] [28] Axillary recurrence information would provide better understanding of the actual benefit of ALND in this population at high risk of both local and distant recurrence.
In conclusion, management of axillary disease in breast cancer has evolved significantly over the past few decades. Although randomized clinical trial data have shown that SLNB alone is adequate in women with low-volume nodepositive disease, our results suggest that axillary lymphadenectomy may still benefit women with clinical N2-3 disease, regardless of the sequence of or response to systemic chemotherapy. Further studies are needed to identify select breast cancer patients with advanced nodal disease who can safely avoid surgical lymphadenectomy.
